A. De Vincentis,F. Terracciani,D. D'Amato,M. Scaravaglio,P. Invernizzi,E. Vanni,D. Campion,A. Floreani,N. Cazzagon,D. Alvaro,R. Venere,E.G. Giannini,S. Labanca,A. Lleo,F. Colapietro,E. Degasperi,M. Viganò,E. Pesatori,S. Fagiuoli,M. Marzioni,V. Buzzanca,R. Viganò,F. D'Amico,A. Galli,A. Curto,F. Marra,P. Begini,L. Baiocchi,P. Carnì,L. Muratori,B. Coco,M. Brunetto,F. Pizzolante,N. De Matthaeis,E. Falbo,L. Surace,A. Mattalia,D. Ieluzzi,F. Salomone,G. Delle Monache,R. Tatonetti,I. Cavalli,V. Cossiga,F. Morisco,V. Valiani,P. Gatti,V. Boccaccio,D. Angrisani,G. Vettori,B. Cuffari,A. Moretti,A. Rocco,G. Nardone,P. Scivetti,M. Costanzo,V. Boano,G.F. Manfredi,L. Simone,V. Pace Palitti,M. Russello,M. Cannavò,E. Frazzetto,G. Bertino,M. Di Stefano,A. Izzi,F. Cerini,L. Chessa,M. Miglianti,V. Feletti,A. Mussetto,R. Cozzolongo,F. Losito,G.A. Niro,R. Cotugno,R. Sacco,C. Ricci,P. Poise,L. Cadamuro,A. Castellaneta,F. Squeo,N. Terreni,N. Bina,P. Pozzoni,S. Casella,F. Zani,O. Morelli,G. Cuccorese,C. Saitta,T. Zolfino,C. Rigamonti,V. Calvaruso,M. Carbone,U. Vespasiani-Gentilucci

Abstract:Introduction In PBC, the prognostic value of alkaline phosphatase, bilirubin and liver stiffness measurements(LSM) has been well established. However, the significance of their variation during treatment with obeticholic acid (OCA) has never been investigated. Aim To describe on-treatment trajectories of LSM based on biochemical response to OCA, and to evaluate associated risk of liver-related events (LRE) in a large cohort of OCA-treated PBC patients. Materials and Methods We used data from the Italian RECAPITULATE cohort, including OCA-treated PBC patients from centers belonging to the Italian PBC Registry and/or the CLEO/AIGO PBC study groups. Subjects with <6 months’ observation and cirrhotics in Child-Pugh B-C classes were excluded. Biochemical response was evaluated through POISE criteria. Linear mixed models were used to describe on-treatment variation of LSM, while Cox-models to assess the impact on LRE. Joint models were applied to estimate the association between LSM changes and LRE, defined as the occurrence of liver-related death, liver transplantation, or hepatic decompensation. Results 631 PBC patients (median age 58, women 89%, cirrhosis 27%) accounted for 29 LRE during 19,164 patient-months (median follow-up, 30 months). A sub-cohort of 243 patients with at least two LSMs (total, 656 LSMs) was also analysed. POISE response rates were 42% and 58% at 1 and 3 years, respectively. LSM progressively increased in POISE non-responders (slope +0.44 KPa/year, 95%CI 0.04,0.85), while decreasing over time in responders (slope -0.45 KPa/year 95%CI -0.75,-0.13; p interaction<0.001). Patients attaining 1year-POISE response showed a significantly reduced incidence of LRE during follow-up (HR 0.22, 95%CI 0.08,0.59). Any increase in LSM was associated with an increased risk of LRE, with an overall HR per 10% increase in LSM/year of 1.39 (95%CI 1.18,1.67). Conclusions In patients with PBC, biochemical response to OCA translates into a reduction of LSM and of LRE during follow-up, while non-response is associated with increased LSM and risk of LRE.

S220 Stabilization of Enhanced Liver Fibrosis and Liver Stiffness Measures in the Open-Label Extension of the Phase 3 POISE Trial of Obeticholic Acid for the Treatment of Primary Biliary Cholangitis

Obeticholic Acid—A Pharmacological and Clinical Review

S123 Effect of Obeticholic Acid on Reduction and Normalization of Alanine Aminotransferase and Aspartate Aminotransferase in the Phase 3 POISE Trial in Primary Biliary Cholangitis

Transient Elastography in Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease: A Systemic Review and Meta-Analysis

Biochemical response to obeticholic acid drives liver stiffness variation over time and the risk of liver-related events in patients with primary biliary cholangitis

Safety, pharmacokinetics and pharmacodynamics of obeticholic acid in subjects with fibrosis or cirrhosis from NASH

Changes in liver stiffness using acoustic radiation force impulse imaging in patients with obstructive cholestasis and cholangitis

Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals

Microbiota-induced lipid peroxidation impairs obeticholic acid-mediated antifibrotic effect towards nonalcoholic steatohepatitis in mice

Obeticholic acid for the treatment of primary biliary cirrhosis

Insight into the natural history of primary biliary cirrhosis: A systemic review of data from placebo-controlled clinical trials.

S4334 Inositol and Taurodeoxycholic Acid Adjunctive Therapy in NASH

Longitudinal outcomes of obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice

Impact of Controlled Attenuation Parameter on Detecting Fibrosis Using Liver Stiffness Measurement.

Performance of Transient Elastography in Assessing Liver Fibrosis in Patients with Autoimmune Hepatitis-Primary Biliary Cholangitis Overlap Syndrome

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

Comparison of point shear wave elastography and transient elastography in the evaluation of patients with NAFLD

Comparison Between Liver Stiffness Measurement by Fibroscan and Splenic Volume Index as NonInvasive Tools for the Early Detection of Oxaliplatin-induced Hepatotoxicity

Non-Invasive Assessment of Liver Fibrosis Progression and Prognosis in Primary Biliary Cholangitis

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis